Compositions and methods for cancer therapy

Abstract

The present disclosure generally relates to compositions and methods for cancer immunotherapy, as well as hematopoietic recovery following cancer treatment such as chemotherapy or irradiation.

What is claimed is: 
     
         1 - 17 . (canceled) 
     
     
         18 . A method for cancer immunotherapy, comprising administering to a patient having cancer a therapeutically effective amount of anti-LRP10 antibody or antigen-binding fragment thereof. 
     
     
         19 . The method of  claim 18 , wherein the anti-LRP10 antibody or antigen-binding fragment thereof is an anti-LRP10 antibody. 
     
     
         20 . The method of  claim 18 , wherein the anti-LRP10 antibody or antigen-binding fragment thereof is an LRP10 antigen-binding fragment. 
     
     
         21 . The method of  claim 18 , wherein said anti-LRP10 antibody or antigen-binding fragment thereof enhances tumor infiltration of lymphocytes, thereby providing cancer immunotherapy. 
     
     
         22 . The method of  claim 21 , wherein the lymphocytes are CD8+ T cells and cytotoxic T lymphocytes. 
     
     
         23 . A method for hematopoietic recovery, comprising administering to a patient in need of hematopoietic recovery a therapeutically effective amount of anti-LRP10 antibody or antigen-binding fragment thereof. 
     
     
         24 . The method of  claim 23 , wherein the anti-LRP10 antibody or antigen-binding fragment thereof is an anti-LRP10 antibody. 
     
     
         25 . The method of  claim 24 , wherein the anti-LRP10 antibody or antigen-binding fragment thereof is an LRP10 antigen-binding fragment. 
     
     
         26 . The method of any one of  claim 23 , wherein said anti-LRP10 antibody or antigen-binding fragment thereof enhances recovery of all hematopoietic lineages, in a patient who has received chemotherapy and/or radiotherapy. 
     
     
         27 . The method of  claim 26 , wherein said anti-LRP10 antibody or antigen-binding fragment thereof enhances recovery of lymphoid lineages. 
     
     
         28 . The method of  claim 18 , wherein the anti-LRP10 antibody or antigen-binding fragment thereof is administered parenterally. 
     
     
         29 . The method of  claim 18 , wherein the method further comprises administering at least one additional anti-cancer agent. 
     
     
         30 . The method of  claim 29 , wherein the at least one additional anti-cancer agent is a chemotherapeutic drug, an EGFR inhibitor, a VEGF inhibitor, an anti-ErbB2 antibody, or any combination thereof. 
     
     
         31 . A method for identifying an LRP10 inhibitor, comprising contacting a cell with a test agent, wherein an increase in migration toward a chemotactic stimulus compared to a control cell that is not contacted with the test agent indicates that the test agent is an LRP10 inhibitor, wherein the chemotactic stimulus is selected from C-X-C motif chemokine 12 (CXCL12), C-X-C motif chemokine 10 (CXCL10), sphingosine-1-phosphate (S1P), C-C motif ligand 2 (CCL2), and/or C-C motif ligand 21 (CCL21). 
     
     
         33 . The method of  claim 31 , wherein the test agent is an anti-LRP10 antibody or antigen-binding fragment thereof or a soluble receptor for one or more LRP10 ligands. 
     
     
         34 . The method of  claim 33 , wherein the test agent is a soluble receptor for one or more LRP10 ligands and is an LRP10 Q-Fc chimera. 
     
     
         35 . A method for identifying an LRP10 inhibitor, comprising contacting a cell with a test agent, wherein an increase in expression of Frizzled and/or p21 compared to a control cell that is not contacted with the test agent indicates that the test agent is an LRP10 inhibitor. 
     
     
         36 . The method of  claim 35 , wherein the test agent is an anti-LRP10 antibody or antigen-binding fragment thereof or a soluble receptor for one or more LRP10 ligands. 
     
     
         37 . The method of  claim 36 , wherein the test agent is a soluble receptor for one or more LRP10 ligands and is an LRP10 Q-Fc chimera.